Clinical-stage biotechnology company Evommune Inc announced on Tuesday that a full data set from the Phase 2 trial of EVO756 in adults with chronic inducible urticaria (CIndU) was accepted for a late-breaker oral presentation at the upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress being held in Paris, France from 17-20 September 2025.

The company says that EVO756 is a potent, highly selective oral small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2). By targeting MRGPRX2, EVO756 has potential with a differentiated approach to treating disease, as it is designed to deliver modulation on both mast cells and peripheral sensory neurons. EVO756 is currently in ongoing Phase 2b trials in chronic spontaneous urticaria and atopic dermatitis.

Evommune will host a webcast to review the data being presented at EADV by Edward (Ted) Lain, MD, MBA, a board-certified dermatologist and clinical investigator, as well as members of the Evommune management team.